Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its ...

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Neurocrine Biosciences, Inc. today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial ...

Vertex Pharmaceuticals is prepping for its Q1 earnings reveal on May 5, with analysts expecting mixed results. EPS is ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 2.09% to $498.86 Thursday, on what proved to be an all-around great trading ...